Modeling and Simulation in the Context of Health Technology Assessment: Review of Existing Guidance, Future Research Needs, and Validity Assessment

Background Despite rigorous systematic reviews of efficacy and effectiveness of health care interventions, patients, providers and policymakers may remain in doubt about what they should do because of uncertainty, tradeoffs among benefits and harms, and conflicting preferences. Modeling and simulation studies in health care can supplement systematic reviews to increase the usefulness of the evidence summary. The aims of this report are four-fold: (1) to summarize evidence- and consensus-based guidance on the conduct and reporting of health care modeling and simulation; (2) to summarize guidance from Health Technology Assessment (HTA) groups for modeling; (3) to prioritize future research needs to improve models; and (4) to provide an overview of methods for model calibration and validation. Methods With guidance from a Technical Expert Panel and a Clinical and Policy Advisory team with clinical, methodological research, and policymaking expertise, we completed the following projects: For Aim 1, we conducted a systematic review of articles that provided evidence- or consensus-based recommendations for the conduct and reporting of health care modeling and simulation studies. We classified recommendation statements into four domains: model structure, data, consistency, and communication of model results. To contextualize the findings of the systematic review, we organized a meeting with a group of 28 stakeholders, including modelers, users of models, and funders of research. For Aim 2, we searched the web sites of 126 international agencies and institutes conducting HTA for real-world practices regarding when to apply modeling and simulation methods, which we summarized. For Aim 3, from the systematic review and from the stakeholders in Aim 1 we identified and collected suggestions for future research needs. Stakeholders prioritized those needs based on importance, desirability of new research, feasibility, and potential impact. For Aim 4, we searched for articles that compared or applied alternative validation methods for modeling and simulation. We extracted and summarized descriptions and comparisons of any methods and reported results for face validity, internal validity, external validity, cross-model validation, and calibration. Results The systematic review of modeling recommendations (Aim 1) found 71 eligible articles. 90 percent of articles (n=64) provided recommendations regarding model structure. Almost all articles (n=68, 96%) also provided recommendations regarding obtaining appropriate data to populate models. Stakeholders highlighted the importance of establishing guiding principles for “good practice” but discouraged the use of “cookbook” checklists. Of the 71 articles, 38 (54%) provided suggestions for future research; stakeholders provided 28 additional suggestions. We found 21 HTA organizations provided guidance (Aim 2) through their web sites regarding the application of modeling and simulation in the context of conducting a HTA. The HTA organizations varied widely in what areas of modeling they provided guidance for and what specific recommendations they made. In general, HTA organizations favored incorporating models into HTA, provided recommendations on how to model data and structure, and recommended inclusion of costs in cost-effectiveness models. Future research needs that were prioritized (Aim 3) included questions about model data, model structure, consistency, and reporting. Studies comparing validation methods (Aim 4) provided information on model validation (face validity and internal, external, and cross-model validation) and calibration (varying specifications of the calibration problem with the same and different algorithms and use of alternative algorithms for the same calibration problem). Conclusion Our systematic review and stakeholder meeting summary provides a comprehensive compendium of guidance documents for modeling and simulation studies, annotated with information on the domains covered by each document, and the methods used to arrive at specific recommendations. We also summarized modeling recommendations for HTA organizations. These processes enabled us to prioritize future research needs to form an empirical basis for and to improve recommendations for modeling. Our overview of model validation and calibration provides insights into the relative value and efficiency of different methods.

[1]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[2]  Ross D. Shachter,et al.  A Bayesian Method for Synthesizing Evidence: The Confidence Profile Method , 1990, International Journal of Technology Assessment in Health Care.

[3]  Uwe Siebert,et al.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  J Mullahy What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. , 1996, Medical care.

[5]  M. Drummond,et al.  Standardizing Methodologies for Economic Evaluation in Health Care: Practice, Problems, and Potential , 1993, International Journal of Technology Assessment in Health Care.

[6]  Uwe Siebert,et al.  Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure , 2011, PharmacoEconomics.

[7]  Uwe Siebert,et al.  Systematic assessment of decision models in Parkinson's disease. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  Nicholas J Wald,et al.  Teleoanalysis: combining data from different types of study , 2003, BMJ : British Medical Journal.

[9]  Michael Willis,et al.  Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM) , 2013, Journal of medical economics.

[10]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[11]  M Sculpher,et al.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.

[12]  M C Weinstein,et al.  Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. , 1997, PharmacoEconomics.

[13]  Gail Gong,et al.  Pseudo Maximum Likelihood Estimation: Theory and Applications , 1981 .

[14]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making Inconsistency in Networks of Evidence Based on Randomized Controlled Trials. , 2013 .

[16]  Kristian Bolin,et al.  Economic Evaluation of Smoking-Cessation Therapies , 2012, PharmacoEconomics.

[17]  Jonathan Karnon,et al.  Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  Natasha K Stout,et al.  Empirically evaluating decision-analytic models. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  Isao Kamae,et al.  The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  Rob Deardon,et al.  Goodness-of-fit measures for individual-level models of infectious disease in a Bayesian framework. , 2011, Spatial and spatio-temporal epidemiology.

[21]  Maarten J. Postma,et al.  Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes , 2012, PharmacoEconomics.

[22]  Amy J Grizzle,et al.  Industry's Perception of Presenting Pharmacoeconomic Models to Managed Care Organizations , 2003, Journal of managed care pharmacy : JMCP.

[23]  Eloise E Kaizar Estimating treatment effect via simple cross design synthesis , 2011, Statistics in medicine.

[24]  Josephine Mauskopf,et al.  Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  Dimitris Bertsimas,et al.  On the Efficiency-Fairness Trade-off , 2012, Manag. Sci..

[26]  Sean D Sullivan,et al.  Quality of clinical and economic evidence in dossier formulary submissions. , 2007, The American journal of managed care.

[27]  Chung Yin Kong,et al.  Development, Calibration, and Validation of a U.S. White Male Population-Based Simulation Model of Esophageal Adenocarcinoma , 2010, PloS one.

[28]  David J Spiegelhalter,et al.  Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modelling , 2003, Statistics in medicine.

[29]  D J Spiegelhalter,et al.  Approximate cross‐validatory predictive checks in disease mapping models , 2003, Statistics in medicine.

[30]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 6: Embedding Evidence Synthesis in Probabilistic Cost-effectiveness Analysis. , 2013 .

[31]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 5: The Baseline Natural History Model. (5), , 2013 .

[32]  K. Schittkowski,et al.  NONLINEAR PROGRAMMING , 2022 .

[33]  C C Blackmore,et al.  Methodologic evaluation of the radiology cost-effectiveness literature. , 1997, Radiology.

[34]  R. Kane,et al.  Decision and Simulation Modeling in Systematic Reviews , 2013 .

[35]  E Goyder,et al.  A review and critique of modelling in prioritising and designing screening programmes. , 2007, Health technology assessment.

[36]  Milton C. Weinstein,et al.  Incorporating Calibrated Model Parameters into Sensitivity Analyses , 2012, PharmacoEconomics.

[37]  Jonathan Karnon,et al.  Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective , 2008, The European Journal of Health Economics.

[38]  G. Seage,et al.  Individual-Based Simulation Models of HIV Transmission: Reporting Quality and Recommendations , 2013, PloS one.

[39]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 1: Introduction. Medical Decision Making, , 2013 .

[40]  George W. Torrance,et al.  The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals , 1999, PharmacoEconomics.

[41]  Simon Dixon,et al.  Testing the Validity of Cost-Effectiveness Models , 2000, PharmacoEconomics.

[42]  Katarzyna Kolasa,et al.  What aspects of the health technology assessment process recommended by international health technology assessment agencies received the most attention in Poland in 2008? , 2011, International Journal of Technology Assessment in Health Care.

[43]  Jennifer A. Roberts,et al.  Economic Evaluation of Diagnostic Technology: Methodological Challenges and Viable Solutions , 1997, International Journal of Technology Assessment in Health Care.

[44]  S W Duffy,et al.  Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility. , 2002, Journal of cancer epidemiology and prevention.

[45]  M. Gold,et al.  Panel on cost-effectiveness in health and medicine. , 1996, Medical care.

[46]  Stuart Brody,et al.  Plausible and implausible parameters for mathematical modeling of nominal heterosexual HIV transmission. , 2007, Annals of epidemiology.

[47]  D Menon,et al.  Canada's new guidelines for the economic evaluation of pharmaceuticals. , 1996, Medical care.

[48]  David M. Eddy,et al.  Meta-analysis by the confidence profile method , 1992 .

[49]  Milton C. Weinstein,et al.  Recommendations for Reporting Cost-effectiveness Analyses , 1996 .

[50]  D B Evans,et al.  Development of WHO guidelines on generalized cost-effectiveness analysis. , 2000, Health economics.

[51]  Jill M Ferdinands,et al.  Obstructive Lung Disease Models: What Is Valid? , 2008, COPD.

[52]  Johan L. Severens,et al.  Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands , 2012, PharmacoEconomics.

[53]  Andrea Manca,et al.  Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies , 2005, International Journal of Technology Assessment in Health Care.

[54]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[55]  Suzanne L. West,et al.  CLINICAL HETEROGENEITY IN SYSTEMATIC REVIEWS AND HEALTH TECHNOLOGY ASSESSMENTS: SYNTHESIS OF GUIDANCE DOCUMENTS AND THE LITERATURE , 2012, International Journal of Technology Assessment in Health Care.

[56]  H. D. de Vet,et al.  Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria , 2005, International Journal of Technology Assessment in Health Care.

[57]  Anna García-Altés,et al.  Spanish recommendations on economic evaluation of health technologies , 2010, The European Journal of Health Economics.

[58]  S. Goodman,et al.  Reproducible Research: Moving toward Research the Public Can Really Trust , 2007, Annals of Internal Medicine.

[59]  R. Platt,et al.  Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.

[60]  Janneke P C Grutters,et al.  Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[61]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[62]  A. Gelman A Bayesian Formulation of Exploratory Data Analysis and Goodness‐of‐fit Testing * , 2003 .

[63]  G Scott Gazelle,et al.  Calibration of disease simulation model using an engineering approach. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[64]  Cathal Walsh,et al.  Bayesian Calibration of a Natural History Model with Application to a Population Model for Colorectal Cancer , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[65]  Kyle R. Douglas-Mankin,et al.  Hydrologic and Water Quality Models: Use, Calibration, and Validation , 2012 .

[66]  Joseph Lau,et al.  Decision-Analytic Modeling to Evaluate Benefits and Harms of Medical Tests: Uses and Limitations , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[67]  Jonathan Karnon,et al.  Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions , 2011, PharmacoEconomics.

[68]  M J Nuijten,et al.  Reporting format for economic evaluation. Part II: Focus on modelling studies. , 1998, PharmacoEconomics.

[69]  Iris Lansdorp-Vogelaar,et al.  A Systematic Comparison of Microsimulation Models of Colorectal Cancer , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[70]  L. Mantovani,et al.  A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics. , 1995, PharmacoEconomics.

[71]  P Barton,et al.  Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. , 2009, Health technology assessment.

[72]  Javier Soto,et al.  HEALTH ECONOMIC EVALUATIONS USING DECISION ANALYTIC MODELING , 2002, International Journal of Technology Assessment in Health Care.

[73]  Uwe Siebert,et al.  EBM, HTA, and CER: clearing the confusion. , 2010, The Milbank quarterly.

[74]  F A Sonnenberg,et al.  Toward a Peer Review Process for Medical Decision Analysis Models , 1994, Medical care.

[75]  E. Lee,et al.  Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[76]  J Chilcott,et al.  Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. , 2010, Health technology assessment.

[77]  M Sculpher,et al.  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.

[78]  Jonathan Karnon,et al.  Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases , 2013, Applied Health Economics and Health Policy.

[79]  A S Detsky,et al.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. , 1993, PharmacoEconomics.

[80]  S. Zeger,et al.  Latent Class Model Diagnosis , 2000, Biometrics.

[81]  F. Pang,et al.  Generalisability in economic evaluation studies in healthcare: a review and case studies. , 2004, Health technology assessment.

[82]  Daniela De Angelis,et al.  Mathematical models for the study of HIV spread and control amongst men who have sex with men , 2011, European Journal of Epidemiology.

[83]  C. Bell,et al.  The Quality of Reporting in Published Cost-Utility Analyses, 19761997 , 2000, Annals of Internal Medicine.

[84]  Murray Krahn,et al.  Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[85]  Yola Moride,et al.  Validation of a decision model for preventive pharmacological strategies in postmenopausal women , 2004, European Journal of Epidemiology.

[86]  A E Ades,et al.  Markov Chain Monte Carlo Estimation of a Multiparameter Decision Model: Consistency of Evidence and the Accurate Assessment of Uncertainty , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[87]  Günther Zauner,et al.  Appropriate Evidence Sources for Populating Decision Analytic Models Within Health Technology Assessment (HTA): A Systematic Review of HTA Manuals and Health Economic Guidelines , 2013 .

[88]  A E Ades,et al.  Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. , 2006, Health economics.

[89]  C. Gouriéroux,et al.  PSEUDO MAXIMUM LIKELIHOOD METHODS: THEORY , 1984 .

[90]  Xiao-Li Meng,et al.  POSTERIOR PREDICTIVE ASSESSMENT OF MODEL FITNESS VIA REALIZED DISCREPANCIES , 1996 .

[91]  Michael T French,et al.  Economic evaluation of telemedicine: review of the literature and research guidelines for benefit-cost analysis. , 2009, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

[92]  G A Colditz,et al.  Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature , 1992, Annals of Internal Medicine.

[93]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.

[94]  Vivek Pawar,et al.  Methods of Model Calibration , 2012, PharmacoEconomics.

[95]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[96]  Carol Bennett,et al.  Reporting guidelines for modelling studies , 2012, BMC Medical Research Methodology.

[97]  W. Ungar,et al.  The Pediatric Quality Appraisal Questionnaire: an instrument for evaluation of the pediatric health economics literature. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[98]  Milton C. Weinstein,et al.  Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.

[99]  Alex J. Sutton,et al.  Heterogeneity: Subgroups, Meta-Regression, Bias And Bias-Adjustment , 2011 .

[100]  J. Hay,et al.  Panel 2: methodological issues in conducting pharmacoeconomic evaluations--modeling studies. , 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[101]  C. Mullins,et al.  Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. , 2002, PharmacoEconomics.

[102]  Paul C Langley Modeling for health care and other policy decisions: uses, roles, and validity. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[103]  Uwe Siebert,et al.  Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia , 2014, Applied Health Economics and Health Policy.

[104]  B Lovatt,et al.  The United Kingdom guidelines for the economic evaluation of medicines. , 1996, Medical care.

[105]  J B Wong,et al.  Validating a Markov Model of Treatment for Hepatitis C Virus-related Hepatocellular Carcinoma , 2008, Methods of Information in Medicine.

[106]  Christian Weber,et al.  German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[107]  M C Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[108]  Michel Huybrechts,et al.  Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[109]  Nicky J Welton,et al.  Multiparameter evidence synthesis in epidemiology and medical decision-making , 2008, Journal of health services research & policy.

[110]  D. Pieper,et al.  Methods of international health technology assessment agencies for economic evaluations- a comparative analysis , 2013, BMC Health Services Research.

[111]  J. Mason,et al.  The Generalisability of Pharmacoeconomic Studies , 1997, PharmacoEconomics.

[112]  J. Savarino,et al.  Bayesian Calibration of Microsimulation Models , 2009, Journal of the American Statistical Association.

[113]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 7 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[114]  G Scott Gazelle,et al.  Chapter 9: The MGH‐HMS Lung Cancer Policy Model: Tobacco Control Versus Screening , 2012, Risk analysis : an official publication of the Society for Risk Analysis.

[115]  E. Chelimsky,et al.  Cross-design Synthesis: A New Form of Meta-analysis for Combining Results from Randomized Clinical Trials and Medical-practice Databases , 1993, International Journal of Technology Assessment in Health Care.

[116]  J L Severens,et al.  Economic evaluation of diagnostic tests. A review of published studies. , 1999, International journal of technology assessment in health care.

[117]  Mark Jit,et al.  Calibration of Complex Models through Bayesian Evidence Synthesis , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[118]  Richard G. White,et al.  Calibrating Models in Economic Evaluation , 2012, PharmacoEconomics.

[119]  A Liberati,et al.  EUR-ASSESS Project Subgroup Report on Methodology: Methodological Guidance for the Conduct of Health Technology Assessment , 1997, International Journal of Technology Assessment in Health Care.

[120]  Josephine Mauskopf,et al.  Methodological and Conduct Principles for Pharmacoeconomic Research , 1995, PharmacoEconomics.

[121]  John Nixon,et al.  Can economic evaluations be made more transferable? , 2005, The European Journal of Health Economics.

[122]  Carla E. Brodley,et al.  Semi-automated screening of biomedical citations for systematic reviews , 2010, BMC Bioinformatics.

[123]  Sean D Sullivan,et al.  Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies , 2003, Medical care.

[124]  Mark Sculpher,et al.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[125]  J. Caro,et al.  Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[126]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine , 1997 .

[127]  C. Mullins,et al.  Emerging standardization in pharmacoeconomics. , 1998, Clinical therapeutics.

[128]  Simon G Thompson,et al.  Uncertainty and validation of health economic decision models. , 2009, Health economics.

[129]  Natasha K. Stout,et al.  Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines , 2012, PharmacoEconomics.

[130]  Mark Sculpher,et al.  Common Methodological Flaws in Economic Evaluations , 2005, Medical care.

[131]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .

[132]  S Gallivan,et al.  Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK , 2006, British Journal of Cancer.

[133]  R. Peng Reproducible Research in Computational Science , 2011, Science.

[134]  David M. Eddy,et al.  The Confidence Profile Method: A Bayesian Method for Assessing Health Technologies , 1989, Oper. Res..

[135]  Sean D Sullivan,et al.  The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[136]  Thomas Mittendorf,et al.  Methods for determining cost-benefit ratios for pharmaceuticals in Germany , 2007, The European Journal of Health Economics.

[137]  Ross D. Shachter,et al.  An Introduction to a Bayesian Method for Meta-analysis , 1990, Medical decision making : an international journal of the Society for Medical Decision Making.

[138]  Theo Stijnen,et al.  Apparent and Internal Validity of a Monte Carlo–Markov Model for Cardiovascular Disease in a Cohort Follow-up Study , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[139]  D. Legates,et al.  Evaluating the use of “goodness‐of‐fit” Measures in hydrologic and hydroclimatic model validation , 1999 .

[140]  A Gafni,et al.  Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. , 1999, Journal of evaluation in clinical practice.

[141]  Uwe Siebert,et al.  Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease , 2012, PharmacoEconomics.

[142]  Jonathan Karnon,et al.  A Critique and Impact Analysis of Decision Modeling Assumptions , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[143]  Karl Claxton,et al.  Assessing Quality in Decision Analytic Cost-Effectiveness Models , 2000, PharmacoEconomics.

[144]  Paul Meissner,et al.  A New Taxonomy for Stakeholder Engagement in Patient-Centered Outcomes Research , 2012, Journal of General Internal Medicine.

[145]  Jeffrey G. Arnold,et al.  Model Evaluation Guidelines for Systematic Quantification of Accuracy in Watershed Simulations , 2007 .

[146]  Simon Capewell,et al.  Coronary heart disease policy models: a systematic review , 2006, BMC public health.

[147]  James J. Heckman,et al.  The Empirical Foundations of Calibration , 1996 .

[148]  N. Welton,et al.  Estimation of Markov Chain Transition Probabilities and Rates from Fully and Partially Observed Data: Uncertainty Propagation, Evidence Synthesis, and Model Calibration , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[149]  B R Luce,et al.  Methods of cost-effectiveness analysis: areas of consensus and debate. , 1995, Clinical therapeutics.

[150]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 2 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[151]  J. Elston,et al.  The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. , 2009, Health technology assessment.

[152]  Suzy Paisley Classification of evidence in decision-analytic models of cost-effectiveness: a content analysis of published reports. , 2010, International journal of technology assessment in health care.

[153]  Ben S Cooper,et al.  Confronting models with data. , 2007, The Journal of hospital infection.